ReadyRx review

The catalog here is broad and the peptide lines are priced sensibly, but the GLP-1 is the expensive item rather than the cheap one. The semaglutide floor sits above what most providers reviewed here charge for the same molecule, and above every other product on its own shelf. That is worth establishing before starting an intake, because the shape of the site suggests a low-cost peptide clinic while the line most readers arrive for is the one priced highest on it. Two structural gaps compound the problem. Every figure is a starting point with nothing published about what it starts from, so a number already above the median is a floor above the median rather than a rate anyone is quoted. And no tirzepatide price appears beside the semaglutide one, so a reader cannot compare the two molecules here at all, or even establish whether the dual agonist is offered. No dose sits behind any figure either. What the site does state clearly is that insurance is not required, and its non-GLP-1 lines are priced in a way that makes them easy to compare against other peptide sellers.

Vs median

$86/mo above the $169 median across the 242 of 373 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Standard plan, self-directed low dose

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Varies by dose, plan or tier

Price last updated

August 2026

ReadyRx dispenses through a Not named facility. No bloodwork is required before you start. A clinician review is included in the price.

The catalog here is broad and the peptide lines are priced sensibly, but the GLP-1 is the expensive item rather than the cheap one — the semaglutide floor sits above what most providers reviewed here charge, and above every other product on its own shelf. That is worth knowing before starting an intake, because the shape of the site suggests a low-cost peptide clinic while the line most readers arrive for is the one priced highest. Two structural gaps compound it. Every figure is a starting point with nothing published about what it starts from, so the number above the median is a floor above the median rather than a rate. And there is no tirzepatide price published beside the semaglutide one, so a reader cannot compare the two molecules here at all, or work out whether the dual agonist is offered. No dose appears behind any figure either. What the site does state clearly is that insurance is not required, and the non-GLP-1 lines are priced in a way that makes them genuinely easy to compare against other peptide sellers.

The semaglutide figure sits above the median for compounded plans, and is a floor.

• No tirzepatide price is published, so the two molecules cannot be compared.
• No dose is published behind any figure and no pharmacy is named.

ReadyRx is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What microdosing GLP-1 costs
• What the evidence actually shows
• The true annual cost of a plan
• What a flat price costs at a low dose